- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01070758
Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy
Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump
The purpose of our study is to evaluate the efficacy and safety of Lanreotide Autogel in children with congenital hyperinsulinism already treated with Octreotide by pump.
Congenital hyperinsulinism is a genetic disorder characterized by inappropriate insulin secretion resulting in persistent hypoglycemia (low blood sugars. Patients exposed to recurrent hypoglycemic episodes are at increased risk of developmental disorders, so identification and prompt management of patients are essential. Many patients are treated with the somatostatin analog Octreotide which is administered by continuous infusion using a pump (we use an insulin pump). This treatment may pose a huge burden and be stressful for patients and families as it demands intensive daily care. In an effort to simplify the daily care of our patients and improve their quality of life we will study the efficacy and safety of Lanreotide Autogel - a long-acting somatostatin analog that can be administered by injection once a month
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of our study is to evaluate the efficacy and safety of Lanreotide Autogel in children with CHI already treated with Octreotide by pump.
Patients and methods. Congenital hyperinsulinism (CH) is a genetic disorder characterized by dysregulated insulin secretion resulting in persistent hypoglycemia. Identification and prompt management of patients are essential, as patients exposed to recurrent hypoglycemic episodes are at increased risk of developmental disorders. Many patients are treated with the somatostatin analog Octreotide which is administered by continuous infusion using a pump. This treatment may pose a huge burden and be stressful for patients and families as it demands intensive daily care. In an effort to simplify the daily care of our patients and improve their quality of life we will study the efficacy and safety of Lanreotide Autogel(Lan-ATG)- a long-acting somatostatin analog that can be administered by injection once a month.
This trial will include children with CH, who are treated with Octreotide by pump. We believe that children older than 2 years old will benefit most from this therapy. At this age, some of the parents encounter technical problems with the pump, as the children are prone to play with the pump and take out the needles. It's also very difficult to place the children in day care, because they need continuous follow up.
The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
The patients will be gradually weaned from the pump following the first injection of Lan-ATG (10% decrease every 3-4 days for a total of a month).
Every patient will serve as his/her own control.
The following examinations will be done in every child:
- Continuous blood glucose monitoring during 72 hours with a glucosensor, to exclude asymptomatic hypoglycemia - once in 6 months.
- Growth velocity every 3 months.
- Bone age once a year.
- Routine laboratory tests (biochemistry, CBC and thyroid function tests) every six months.
- Biliary US once in 6 months. During the follow up we will try to expand the distance between injections, based on our knowledge that most of the patients with CH are known to enter remission after the age of 4-5 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Dalit Modan, M.D.
- Phone Number: +972-3-5305015
- Email: dmodan@sheba.health.gov.il
Study Contact Backup
- Name: Kineret Mazor, M.D.
- Phone Number: +972-3-5305015
- Email: Kineret.Mazor@sheba.health.gov.il
Study Locations
-
-
-
Tel-Hashomer, Ramat-Gan, Israel, 52653
- Recruiting
- Pediatric Endocrinology Unit, Sheba Medical Center
-
Contact:
- Dalit Modan, M.D.
- Phone Number: +972-3-5345410
- Email: dmodan@sheba.health.gov.il
-
Principal Investigator:
- Dalit Modan, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 2-8 years,
- Diagnosed with congenital hyperinsulinism,
- Treated by Octreotide continuous infusion (pump).
Exclusion Criteria:
- Family not interested in participating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Euglycemia as recorded by Continuous Glucose Monitoring System (CGMS)
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dalit Modan, M.D., Sheba Medical Ceter, Tel-Hashomer, Israel
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-10-7165-DM-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Hyperinsulinism
-
University Medicine GreifswaldCompletedNon-focal Congenital HyperinsulinismGermany
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedPersistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) | Congenital Hyperinsulinism (CHI)United States
-
Beijing Children's HospitalCompletedCongenital Hyperinsulinaemic Hypoglycaemia | Octreotide Adverse ReactionChina
-
University Hospital, Basel, SwitzerlandGottfried und Julia Bangerter-Rhyner-StiftungRecruitingEndogenous HyperinsulinismSwitzerland
-
Miguel PampaloniRecruitingCongenital HyperinsulinismUnited States
-
Zealand PharmaCompletedCongenital HyperinsulinismUnited States, United Kingdom, Germany, Israel
-
Montefiore Medical CenterNo longer availableCongenital HyperinsulinismUnited States
-
Diva De LeonTerminatedCongenital HyperinsulinismUnited States
-
Diva De LeonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedCongenital HyperinsulinismUnited States
-
Assistance Publique - Hôpitaux de ParisNovartisCompleted
Clinical Trials on Lanreotide autogel
-
IpsenCompleted
-
IpsenCompletedNon Functioning Entero-pancreatic Endocrine TumourUnited Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
-
IpsenCompleted
-
Asan Medical CenterSamsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaboratorsRecruitingNeuroendocrine TumorsKorea, Republic of
-
IpsenCompletedGastroenteropancreatic Neuroendocrine TumorChina
-
IpsenCompletedAcromegalyFrance, Switzerland
-
University Hospital, GhentIpsenCompleted
-
IpsenCompletedMidgut Neuroendocrine Tumours | Pancreatic TumoursSpain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
-
IpsenCompletedNeuroendocrine Tumour With Carcinoid SymptomsDenmark, Norway, Sweden
-
IpsenTerminatedIntestinal ObstructionItaly